An anti-IL-1β monoclonal antibody (canakinumab) is approved for use in autoinflammatory syndromes and recombinant IL-1R antagonist (anakinra) for rheumatoid arthritis, suggesting a potential role for these drugs in other inflammatory conditions. Here, IL1B is linked to autoinflammatory syndrome.